UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
[News Focus] Abbvie hits back at competitors selling Humira biosimilars in Europe
Abbvie is retaliating hard against the firms, which are marketing Humira’s ...
by Lee Han-soo
|
2019-04-15 15:19
라인
All Invossa products contained 293 cells, Kolon confirms
Kolon Life Science said all of the cells used for manufacturing Invossa &nd...
by Jeong Sae-im
|
2019-04-15 11:31
라인
Invossa license won’t be revoked: Kolon CEO
Kolon Life Science remained confident that the regulator would not nullify ...
by Jeong Sae-im
|
2019-04-12 11:40
라인
Regulator, Kolon rebuked for slow response to Invossa problem
Late February: Kolon Life Science, Kolon TissueGene recognize mislabeled ce...
by Jeong Sae-im
|
2019-04-11 14:46
라인
Canada OKs Celltrion’s Truxima
Celltrion said Thursday that it has received regulatory approval for Truxim...
by Lee Han-soo
|
2019-04-11 11:33
라인
Patients may file class-action lawsuit against Kolon for mislabeling Invossa
Korean patients, who received Invossa-K injection for degenerative arthriti...
by Jeong Sae-im
|
2019-04-10 14:41
라인
Celltrion, iProgen to co-develop novel antibody-drug conjugates
Celltrion has signed a development partnership agreement with iProgen Biote...
by Lee Han-soo
|
2019-04-09 16:04
라인
Kolon’s foreign partners await cell analysis results
The overseas business partners of Kolon Life Science are waiting for the re...
by Jeong Sae-im
|
2019-04-08 14:28
라인
Kolon Life Science criticized for poor quality control on Invossa
Researchers are raising suspicions over the Kolon Life Science’s clarificat...
by Jeong Sae-im
|
2019-04-05 12:27
라인
‘Invossa, first treatment to have used cancerous cell lines’
Biotech experts raised a safety concern for Invossa-K, a degenerative arthr...
by Jeong Sae-im
|
2019-04-04 15:24
라인
Celltrion completes patient registration for Humira biosimilar
Celltrion said Thursday that it has completed registering patients for its ...
by Lee Han-soo
|
2019-03-28 18:04
라인
Alteogen wins patent on SC injection formulation for Herceptin biosimilar
Alteogen said Wednesday that it has patented a formulation for ALT-LS2, a s...
by Lee Han-soo
|
2019-03-28 15:04
라인
GC’s US branch opens new plasma collection centers
GCAM (Green Cross America), GC’s U.S. offshoot, said Tuesday that it has op...
by Lee Han-soo
|
2019-03-27 10:43
라인
Celltrion licenses out hypertrophic cardiomyopathy treatment to Japan
Celltrion said Monday that it has signed an exclusive sales agreement with ...
by Lee Han-soo
|
2019-03-25 15:41
라인
Regulator OKs Medipost’s P1 trial of knee osteoarthritis treatment
Medipost said Thursday that the Ministry of Food and Drug Safety has approv...
by Lee Han-soo
|
2019-03-22 14:22
라인
Samsung Bioepis unveils 3-year follow-up data for Ontruzant
Samsung Bioepis said Friday that it has presented the three-year follow-up ...
by Lee Han-soo
|
2019-03-22 14:05
라인
'US sales of Truxima imminent'
Celltrion Chairman Seo Jung-jin said Wednesday that U.S. sales for Truxima,...
by Jeong Sae-im
|
2019-03-20 17:59
라인
Samsung BioLogics, Eutilex to develop anti-cancer immunotherapies
Samsung BioLogics said Wednesday that it has signed a contract development ...
by Lee Han-soo
|
2019-03-20 17:18
라인
Samsung Bioepis nullifies patents related to Herceptin in Korea
Samsung BioEpis has succeeded in nullifying the patent for cancer treatment...
by Lee Han-soo
|
2019-03-18 15:51
라인
Thea, OliX to cooperate in developing age-related macular degeneration treatment
OliX Pharmaceuticals said Monday it has signed a license and collaboration ...
by Lee Han-soo
|
2019-03-18 12:02
-
이전
11
12
13
14
15
16
17
18
19
20
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top